최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.32 no.12, 2022년, pp.962 - 970
김혜란 (부산대학교 한의학전문대학원 한의학과) , 정대영 (부산대학교 한의학전문대학원 한의학과) , 김세이 (부산대학교 한의학전문대학원 한의학과) , 정명호 (부산대학교 한의학전문대학원 한의학과)
Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease (NAFLD) that highly increases the risk of cirrhosis and liver cancer, and there are few therapeutic options available in the clinic. Poricoic acid (PoA), a component of Poria cocos Wolf, has a wide range...
Chen, D. Q., Feng, Y. L., Chen, L., Liu, J. R., Wang, M., Vaziri, N. D. and Zhao, Y. Y. 2019. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic. Biol. Med. 134, 484-497.
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. and Sanyal, A. J. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908-922.
Ipsen, D. H., Lykkesfeldt, J. and Tveden-Nyborg, P. 2018. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 75, 3313-3327.
Kikuchi, T., Uchiyama, E., Ukiya, M., Tabata, K., Kimura, Y., Suzuki, T. and Akihisa, T. 2011. Cytotoxic and apoptosis-inducing activities of triterpene acids from Poria cocos. J. Nat. Prod. 74, 137-144.
Kim, J. H., Sim, H. A., Jung, D. Y., Lim, E. Y., Kim, Y. T., Kim, B. J. and Jung, M. H. 2019. Poria cocus wolf extract ameliorates hepatic steatosis through regulation of lipid metabolism, inhibition of ER stress, and activation of autophagy via AMPK activation. Int. J. Mol. Sci. 20, 4801.
Li, Q., Ming, Y., Jia, H. and Wang, G. 2021. Poricoic acid A suppresses TGF-β1-induced renal fibrosis and proliferation via the PDGF-C, Smad3 and MAPK pathways. Exp. Ther. Med. 21, 289.
Nagappan, A., Jung, D. Y., Kim, J. H., Lee, H. and Jung, M. H. 2018. Gomisin N Alleviates ethanol-induced liver injury through ameliorating lipid metabolism and oxidative stress. Int. J. Mol. Sci. 19, 2601.
Nie, A., Chao, Y., Zhang, X., Jia, W., Zhou, Z. and Zhu, C. 2020. Phytochemistry and pharmacological activities of Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb. Front. Pharmacol. 11. 505249.
Powell, E. E., Wong, V. W. and Rinella, M. 2021. Non-alcoholic fatty liver disease. Lancet 397, 2212-2224.
Rios, J. L. 2011. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 77, 681-691.
Sheka, A. C., Adeyi O., Thompson J., Hameed, B., Crawford, P. A. and Ikramuddin, S. 2020. Nonalcoholic Steatohepatitis. JAMA. 323, 1175-1183.
Schuster, S., Cabrera, D., Arrese, M. and Feldstein, A. E. 2018. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349-364.
Schwabe, R. F., Tabas, I. and Pajvani, U. B. 2020. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913-1928.
Tanaka, N., Aoyama, T., Kimura, S. and Gonzalez, F. J. 2017. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol. Ther. 179,142-157.
Zhang, C. and Yang, M. 2021. Current options and future directions for NAFLD and NASH treatment. Int. J. Mol. Sci. 22, 7571.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.